Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00995137 · ClinicalTrials.gov registry record · Phase 1
Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00995137 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 14 participants.
The verdict
NCT00995137, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).
Interventions
- BIOLOGICAL NK Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00995137
The ClinicalTrials.gov registry entry for NCT00995137 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NK Cell Infusion is the first listed.
NCT00995137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00995137 about?
NCT00995137 is a clinical study titled "Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia". This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT00995137?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00995137?
The interventions under investigation include: NK Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00995137?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.